INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Christie Hospital NHS Foundation Trust
Mánchester, Reino UnidoPublicaciones en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (30)
2024
-
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
Transplantation and Cellular Therapy, Vol. 30, Núm. 1, pp. 93.e1-93.e12
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
2022
-
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Gut, Vol. 71, Núm. 8, pp. 1669-1683
-
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT
British Journal of Haematology, Vol. 196, Núm. 4, pp. 1018-1030
-
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Annals of Oncology, Vol. 33, Núm. 3, pp. 259-275
-
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Blood, Vol. 140, Núm. 21, pp. 2248-2260
2021
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
Hepatology, Vol. 73, Núm. 6, pp. 2311-2325
-
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 2, pp. 97-105
-
REPLY:
Hepatology
-
REPLY:
Hepatology
-
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic
Expert Opinion on Investigational Drugs, Vol. 30, Núm. 4, pp. 377-388
-
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Leukemia, Vol. 35, Núm. 6, pp. 1745-1750
2020
-
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
-
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Haematologica, Vol. 105, Núm. 2, pp. 297-316